Pharmaceuticals & Healthcare · Policy Lab
Pharmacy Benefit Managers
A public research route covering institutions, existing frameworks, possible interventions, and open policy questions.
How to interpret these labels
Urgency is a qualitative editorial assessment of time sensitivity and potential severity in the underlying working research. Addressability is a qualitative assessment of whether identifiable institutions and public interventions may materially affect the issue. The labels are research triage categories; they are not measured forecasts, comparative rankings, or recommendations. Recheck both classifications against current primary sources before use.
Possible public intervention
Structural separation legislation. Spread pricing ban. Rebate transparency mandates. FTC enforcement of anticompetitive practices.
Institutions to examine
- FTC
- HHS
- CMS
- State pharmacy boards
Institution abbreviations
- FTC
- Federal Trade Commission
- HHS
- U.S. Department of Health and Human Services
- CMS
- Centers for Medicare & Medicaid Services
- HELP
- U.S. Senate Committee on Health, Education, Labor, and Pensions
Existing frameworks and precedents
- FTC Pharmacy Benefit Management Investigation (2024)
- State spread pricing bans (growing)
- CMS rebate reform proposals
Open policy gap
Structural separation legislation needed. FTC investigation active. Spread pricing ban advancing. Three companies control 80% of the market — they are the buyer, the seller, and the middleman.
Legislative and policy forums
- HELP
- Finance
- Energy & Commerce
- Judiciary
- ENVI
Continue the research
Use Reform Pathfinder to locate jurisdiction-specific institutions and possible action paths. Use the public glossary for terminology and the selected publications for public evidence and methods.
Research-use notice. This material is for research and educational use. Information may be incomplete or out of date. Verify primary sources, current law, institutional authority, source dates, and local applicability before acting. This site does not provide legal, financial, investment, regulatory, or implementation advice.